UNJHA FORMULATIONS LTD. (UNJHAFOR) Fair Value & Analysis
Healthcare · IN · Market cap ₹87.4M
Strengths
Risks
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 7 days ago
Fair value updated Aug 13, 2026, revised from ₹31.46 to ₹29.28 (−6.9%) since Jul 6, 2026. Share price +35.9% over the past month.
A solid business, screening 10% undervalued on our models.
What matters now
- A fairly wide model range (₹20.99 to ₹40.44) leaves room in how you read the outcome.
- Our model range runs from ₹20.99 (bear) to ₹40.44 (bull), base ₹29.28. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 69/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹7.50 – ₹37.00 · fair‑value band ₹20.99 – ₹40.44 · the ₹26.50 price screens below the ₹29.28 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
UNJHA FORMULATIONS LTD. (UNJHAFOR) currently trades at ₹26.50, while our model-based Fair Value estimate is ₹29.28, implying the stock looks roughly 10.5% undervalued today. The Quality Score stands at 69/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, UNJHA FORMULATIONS LTD. generated revenue of ₹157M at a net margin of 4.5%. Revenue grew 39.2% year over year. It earns a return on equity of 20.2%. The stock trades on a trailing P/E of 16.9. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹20.99 (bear case) to ₹40.44 (bull case); at ₹26.50, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 13% below its 52-week high and 51% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -40% fair-value upside, at 10%, UNJHAFOR screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (₹33.69) versus Asset-Based (₹5.75). Highest evidence: Growth DCF (80).
Notify me when UNJHAFOR reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 72 · Market factors (momentum, volatility) 50
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Unjha Formulations Limited engages in the manufacture and sale of ayurvedic products in India. It offers sat-isabgol and isabgo husk formulation in elaichi flavor under the Anchor name; and isabgol powder in orange flavor under the Fibron and Fibron SF names. The company also exports its products.
Full company description
Unjha Formulations Limited engages in the manufacture and sale of ayurvedic products in India. It offers sat-isabgol and isabgo husk formulation in elaichi flavor under the Anchor name; and isabgol powder in orange flavor under the Fibron and Fibron SF names. The company also exports its products. Unjha Formulations Limited was incorporated in 1994 and is based in Sidhpur, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
UNJHA FORMULATIONS LTD. reported revenue of ₹156M in FY2026 versus ₹142M in FY2022, a compound +2.4%/yr. Reported net income was ₹7.0M in FY2026, compounding +29.3%/yr from FY2022.
Watch UNJHAFOR: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 638 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$56.05 | HK$33.59 | -40% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,525 | ₹1,228 | -86% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare UNJHA FORMULATIONS LTD. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is UNJHA FORMULATIONS LTD. (UNJHAFOR) overvalued or undervalued?
What is the fair value of UNJHAFOR?
What is the quality score of UNJHAFOR?
What is the revenue of UNJHA FORMULATIONS LTD. (UNJHAFOR)?
What is the net profit margin of UNJHAFOR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track UNJHA FORMULATIONS LTD. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.